Zhu Dagny, Ren Shijie, Mills Kayla, Hull Jessie, Dhariwal Mukesh
NVISION Eye Centers, 17980 Castleton Street, Rowland Heights, CA, 91748, USA.
The University of Sheffield, Sheffield, UK.
Ophthalmol Ther. 2023 Apr;12(2):1157-1171. doi: 10.1007/s40123-023-00657-5. Epub 2023 Feb 6.
A systematic literature review and meta-analysis was conducted to identify and obtain a precise single summary estimate on complete spectacle independence after bilateral implantation of a trifocal intraocular lens (IOL) (AcrySof PanOptix, TFNTXX/TFATXX) for patients undergoing cataract surgery.
A search was conducted in PubMed from January 2017 to September 2021. Relevant congress presentations were also searched to include data from completed studies not yet published. Search terms included the intervention (TFNTXX, TFATXX, PanOptix) and outcomes of interest (patient-reported spectacle independence rates). A Bayesian random-effects meta-analysis was conducted, providing a pooled estimate (median and its 95% credible interval) of complete spectacle independence rates among cataract surgery patients. Subgroup analyses evaluated spectacle independence after cataract surgery across different working distances (near, intermediate, far).
Nineteen unique clinical studies were identified. Based on a meta-analysis of 13 studies (N = 513 patients), the complete spectacle independence rate after cataract surgery with TFNTXX/TFATXX IOL was 91.6% (95% credible interval 86.8-95.9%). Additionally, the spectacle independence rates at each focal point (N = 13 studies, 603 patients) were 89.6% (near), 96.3% (intermediate), and 95.9% (far).
This meta-analysis demonstrated that at least nine out of ten patients receiving TFNTXX/TFATXX trifocal IOL during cataract surgery can expect to achieve complete spectacle independence. This study provides informative data for clinicians and patients to feel confident in the use of trifocal intraocular lenses as presbyopia-correcting IOLs that offer high rates of complete spectacle independence.
进行了一项系统的文献综述和荟萃分析，以确定并获得接受白内障手术患者双侧植入三焦点人工晶状体（IOL）（AcrySof PanOptix，TFNTXX/TFATXX）后完全摆脱眼镜依赖的确切单一汇总估计值。
于2017年1月至2021年9月在PubMed上进行检索。还检索了相关的大会报告，以纳入尚未发表的完整研究数据。检索词包括干预措施（TFNTXX、TFATXX、PanOptix）和感兴趣的结果（患者报告的摆脱眼镜依赖率）。进行了贝叶斯随机效应荟萃分析，得出白内障手术患者完全摆脱眼镜依赖率的汇总估计值（中位数及其95%可信区间）。亚组分析评估了白内障手术后不同工作距离（近、中、远）下的摆脱眼镜依赖情况。
共识别出19项独特的临床研究。基于对13项研究（N = 513例患者）的荟萃分析，使用TFNTXX/TFATXX IOL进行白内障手术后的完全摆脱眼镜依赖率为91.6%（95%可信区间86.8 - 95.9%）。此外，每个焦点处的摆脱眼镜依赖率（N = 13项研究，603例患者）分别为89.6%（近）、96.3%（中）和95.9%（远）。
这项荟萃分析表明，在白内障手术期间接受TFNTXX/TFATXX三焦点IOL的患者中，至少十分之九有望实现完全摆脱眼镜依赖。本研究为临床医生和患者提供了有益的数据，使他们对使用三焦点人工晶状体作为矫正老花眼且完全摆脱眼镜依赖率高的人工晶状体充满信心。
